Mineralys Therapeutics (MLYS) Shares Outstanding (2022 - 2026)

Mineralys Therapeutics has reported Shares Outstanding (Entity) for 5 years, with the latest figure at $82.5 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 55.1% year-over-year to $82.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.5 million (up 55.1% YoY) and the FY2025 annual result came in at $67.7 million, up 35.8% from the prior year.
• Shares Outstanding (Entity) climbed to $82.5 million in Q1 2026 per MLYS's latest filing, from $67.7 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $82.5 million in Q1 2026 and troughed at $5.2 million in Q4 2022.
• A 5-year average of $42.1 million and a median of $49.6 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Entity) surged 696.04% in 2023, then advanced 7.11% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $5.2 million in 2022, then soared by 696.04% to $41.1 million in 2023, then rose by 21.12% to $49.8 million in 2024, then soared by 35.8% to $67.7 million in 2025, then increased by 21.87% to $82.5 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $82.5 million, $67.7 million, and $79.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.